How do I know my peptide cycle is working?
Define the goal first, then track baseline subjective and objective markers. Most peptide effects are slow. End-of-cycle reassessment is the test.
Updated May 8, 2026 · 6 min read
You know a peptide cycle is working by tracking against a goal you defined before starting — not by how you feel on injection day. Most peptide effects are slow, subjective, and only obvious in retrospect at end-of-cycle reassessment. The honest answer for most strength peptides is "you'll know in 4-12 weeks, not in 4-12 days." If your reference point for "working" is acute feel, you'll be perpetually disappointed and quit cycles too early.
The most common mistake is using the wrong evaluation framework — expecting peptides to behave like stimulants or painkillers, when they actually behave like training: cumulative, slow, requires a baseline.
Step one — define the goal before starting
If you didn't define the goal, no protocol can confirm whether it worked. Specific goals look like:
| Vague goal | Better goal |
|---|---|
| "Recover better" | "Reduce pain on right Achilles heel-raise from 6/10 to 2/10" |
| "Get bigger" | "Add 2-4 lb on chest/upper back over 12 weeks while maintaining waist measurement" |
| "Feel better" | "Improve sleep quality — reduce wakeups from average 2.5 to under 1 per night" |
| "Heal my gut" | "Reduce post-meal bloating from daily to under 2x per week" |
| "Body recomp" | "Reduce waist circumference 1 inch while maintaining strength on bench/squat/deadlift" |
The goal needs to be measurable before the first injection. Otherwise you're running an experiment with no outcome variable.
What "working" looks like by peptide class
The expected timeline and signal vary dramatically:
| Peptide class | Onset | Primary signal | When to evaluate |
|---|---|---|---|
| BPC-157, TB-500 | 2-4 weeks for first signal | Reduced pain on trigger movement, improved range of motion | Week 6-12 final reassessment |
| Short-acting GH secretagogues | 1-2 weeks for sleep changes; 8+ weeks for body comp | Sleep quality early; body composition and recovery later | Week 12-16 reassessment |
| Long-acting GH (CJC DAC, MK-677) | 2-4 weeks for water retention; 8+ weeks for IGF-1 elevation | Subjective fullness, IGF-1 bloodwork, body comp | Week 8-12 reassessment with labs |
| IGF-1 LR3 | Days for hypoglycemic feel; 2-3 weeks for fullness | Muscle fullness, training pumps, body comp | Week 4-6 final reassessment |
| MOTS-c | 4-8 weeks | Insulin sensitivity, training tolerance | Week 8-12 with labs |
| GHK-Cu (topical) | 4-8 weeks | Skin appearance, hair changes | Week 8-12 reassessment |
For more detail on the BPC-157 case, see how long does BPC-157 take to work.
Track subjective and objective markers
Don't rely on memory. Document at baseline (before first injection), midway, and end-of-cycle:
Subjective markers
| Marker | How to track |
|---|---|
| Pain on a known trigger movement | 0-10 scale, before/after the movement |
| Sleep quality | Subjective rating + wakeup count + total hours |
| Energy through the day | 0-10 morning/afternoon |
| Recovery between training sessions | Soreness duration after a typical session |
| Mood | Brief daily note |
| Appetite | Particularly relevant for ghrelin agonists (Ipa, MK-677) |
Objective markers
| Marker | How to track | When |
|---|---|---|
| Bloodwork | Standard panel + IGF-1 if running secretagogues | Baseline + end of cycle |
| Body weight | Same time, same conditions | Weekly |
| Body composition | Tape measurements, DEXA if available | Baseline + end |
| Range of motion | Specific to the injury (e.g., shoulder external rotation degrees) | Weekly |
| Training metrics | Working weight on key lifts, time-trial pace, etc. | Per training cycle |
The honest test: if you can't compare end-of-cycle data to baseline data, you can't tell whether the cycle worked. The baseline is more important than the cycle itself.
What "working" does not look like
A useful filter for the wrong signals:
| Wrong signal | Why it doesn't tell you |
|---|---|
| "I felt something on injection day" | Most strength peptides have no acute injection-day feel; placebo signal is real |
| "My energy was up the day after" | Lots of things move energy day-to-day |
| "The first 48 hours felt different" | Mostly placebo or normal day-to-day variation |
| "My friend said I look bigger" | Not a measurable outcome |
| "The bloating started on day 3" | Bloating from MK-677 or GH peptides is a side effect, not an outcome |
| "My libido changed" | Possibly meaningful, but hard to attribute to peptides specifically |
If your only barometer is acute feel, you'll be perpetually disappointed.
The bloodwork case
For GH secretagogues specifically, IGF-1 bloodwork is the cleanest objective marker:
- Baseline IGF-1 before starting the cycle
- End-of-cycle IGF-1 at the same lab, same fasting state
- Expected pattern: elevation in the 20-50% range over baseline for a typical Ipa+CJC cycle; higher with MK-677 or CJC DAC
If your IGF-1 didn't move on a 12-week secretagogue cycle, something is wrong: the dose, the vendor, or the protocol.
For more, see IGF-1 testing for GH peptides and peptides and bloodwork.
When to reassess
The mid-cycle and end-of-cycle reassessment framework:
| Cycle length | Mid-cycle check | End-of-cycle reassessment |
|---|---|---|
| 4-6 weeks (recovery, IGF-1 LR3) | Week 3 — look for any signal | Week 4-6 — full evaluation |
| 8-12 weeks (MK-677, MOTS-c) | Week 4-6 — bloodwork drift, side effects | Week 8-12 — full evaluation with end-cycle labs |
| 12-16 weeks (short-acting GH stack) | Week 6-8 — IGF-1, body comp drift | Week 12-16 — full evaluation, decide cycle 2 |
The end-of-cycle reassessment is the most important moment. Honestly answer:
- Did you meet the goal? (Compare to your written baseline.)
- Were there side effects? (Worth running again at the same dose?)
- Was the protocol matched to the goal, or did the protocol drift?
- Should the next cycle be the same, modified, or different?
When the cycle isn't working
If you've reached the expected onset window without signal:
| Diagnosis | Action |
|---|---|
| Wrong dose | Recompute units from concentration; verify math |
| Wrong vendor | Switch — may be underdosed or impure |
| Wrong peptide for the goal | Some injuries need PT or surgery, not biochemistry |
| Goal was wrong (vague or unmeasurable) | Define more specifically next cycle |
| Onset window not yet reached | Wait — most peptides are slow |
| Confounders (training change, sleep change, etc.) | Look at the rest of your inputs |
For BPC-157 specifically, if you've run 12 weeks without meaningful improvement, stop and reassess the diagnosis. That peptide isn't a universal solvent.
A reasonable framework
Whether your cycle is working comes down to:
- Did you define the goal? If no, fix this for next cycle.
- Did you track baseline? If no, you can't evaluate.
- Has the expected onset window passed? If no, wait.
- Has the signal moved on the markers you defined? If yes, the cycle is working. If no, reassess.
It's that simple — and that hard, because most people skip the baseline step.